Prescription Drug Monitoring Program (heathoregon.org/pdmp)



## 2nd Quarter 2025 Report (Apr. 1 - June 30, 2025)

Percent change evaluated relative to 2nd Quarter 2024

## **Summary**

- As of January 2025, the Oregon PDMP includes Schedule V drugs and veterinarian-prescribed drugs.
- Prescriber enrollment increased to 89%, up from 86% in the 2nd quarter of 2024 (Table 3, Figure 1).
- Gateway automated queries rose 3.1% and web queries increased 3.4% compared to Q2 2024 (Table 1). However, integrated report viewing declined following a 2024 spike in activity.
- Total prescriptions for controlled substances rose 8.6%, largely due to the addition of Schedule V and veterinarian-prescribed drugs (Table 5).
- Stimulant prescriptions continue to increase with amphetamine prescriptions increasing 10% making it the most prescribed drug in the PDMP. Methylphenidate prescriptions also increased 11.2% (Table 5).
- Pregabalin entered the top prescriptions list following the Schedule V inclusion (Table 5).
- PDMP gateway use remains stable with active facilities increasing and active users remaining steady.




 Figure 1 shows the number of prescribers enrolled in the PDMP over time from 2013-2025. Registration has remained consistent since 2018.

Table 1. Oregon Prescriber Enrollment and Use: Apr. 1 - June 30, 2025.

User Type	Prescribers	Enrolled	Web Query	Automated Query	Total Query
All Prescribers (by DEA)	27,077	24,176 (89.3%)	1,262 (5.2%)	14,460 (59.8%)	14,634 (60.5%)
Top 4,000 Prescribers	4,000	3,911 (97.8%)	783 (20.0%)	3,532 (90.3%)	3,590 (91.8%)
Top 2,000 Prescribers	2,000	1,970 (98.5%)	496 (25.2%)	1,793 (91.0%)	1,827 (92.7%)

- 27,077 Oregon providers prescribed controlled substances in Q2 2025.
- At quarter's end, 60.5% of enrolled prescribers, 91.8% of the top 4,000 prescribers, and 92.7% of the top 2,000 prescribers submitted a query through the web portal and/or gateway integration.

 Query activity declined compared to Q2 2024, when 74.5% of enrolled prescribers submitted queries.

Table 2. Special Requests: Apr. 1 - June 30, 2025.

Measure	Count
Patient Records	19
Healthcare Boards	41
Law Enforcement	11
Total Special Requests	71

- 71 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

Table 3. PDMP Queries Summary Statistics: Apr. 1 - June 30, 2025...

User Type	Queries	% Change <sup>1</sup>	Automated Queries	% Change <sup>1</sup>	Reports Viewed	% Change <sup>1</sup>
Healthcare providers	79,231	-4.6%	6,672,471	2.9%	816,370	-14.8%
Pharmacies	56,997	-6.7%	1,539,263	4%	811,246	-25.5%
Delegates	176,404	11.4%	NA	NA	NA	NA
Total Queries <sup>2</sup>	312,803	3.4%	8,211,734	3.1%	1,627,616	-20.5%

<sup>&</sup>lt;sup>1</sup>Percent change evaluated relative to same time period during the prior year.

- Web portal queries increased by 3.4%, with the largest gains among delegates.
- Automated queries increased modestly (3.1%), while integrated report viewing fell 20.5% compared to the spike in query activity from 2024.

<sup>&</sup>lt;sup>2</sup>Query data drawn from Appriss AWARxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query.

Table 4. Activity for PDMP-Enrolled Providers: Apr. 1 - June 30, 2025.

Discipline	Total Accounts (by DEA)	% Change	Web Users	% Change	Integrated Users	% Change
MD/PA/DO	20,753	-0.3%	1,348	-10.0%	16,280	11.2%
NP/CNS-PP	5,700	4.5%	1,203	2.6%	4,354	13.9%
RPh	3,741	8.6%	1,194	-7.4%	643	14.8%
Delegates	3,091	12.1%	1,832	3.7%	NA	NA
DDS/DMD	2,607	-1.5%	302	-6.2%	349	6.4%
ND	602	4.0%	165	-8.8%	482	19.0%


- Usage trends show an increased shift towards integrated use and a reduced use of the web portal.
- All provider groups increased integrated usage, especially NPs (+13.9%), RPh (+14.8%), and NDs (+19.0%).

Table 5. Top Prescriptions: Apr 1 - June 30, 2025.

Drug	Number of Rx	% of all Rx	% Change	
All	1,875,379	100%	8.6%	
Amphetamine	257,381	13.7%	10.0%	
Gabapentin	234,187	12.5%	-1.1%	
Oxycodone	232,937	12.4%	1.5%	
Hydrocodone	190,630	10.2%	-5.8%	
Methylphenidate	119,327	6.4%	11.2%	
Lorazepam	80,358	4.3%	0.8%	
Tramadol	71,033	3.8%	-3.4%	
Testosterone	70,048	3.7%	11.6%	
Pregabalin	61,762	3.3%	NA	
Zolpidem	54,584	2.9%	-5.3%	

- Controlled substance prescribing increased 8.6% over the same quarter last year, largely driven by inclusion of schedule V and veterinarian-prescribed drugs as of 2025.
- Stimulant prescribing continues to increase. Amphetamine (+10%)
  remains the most prescribed drug and methylphenidate prescriptions
  also increased (+11.2%) over this time period.
- Gabapentin and hydrocodone prescriptions decreased (-1.1% and -5.8%, respectively). Oxycodone prescriptions rose slightly (1.5%).
- Testosterone prescriptions rose 11.6% and account for 3.7% of all controlled substance prescriptions.
- Pregabalin entered the top 10 prescriptions and is a schedule V drug new to the PDMP in 2025.

To better understand the users and facilities accessing Gateway, *Figure 2* and *Figure 3* show usage over time.



Oregon facilities only: Active status requires submission of at least one quarterly query, unique by facility ID.

Active facilities grew slightly to 2,178 in Q2 2025.

Figure 3. Active users accessing Gateway integration: 2018-2025

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

30000

Oregon users only: Active status requires submission of at least one quarterly query, unique by NPI or DEA number.

• 23,816 users submitting at least one query, consistent with prior quarters.

Contact: PDMP Research Analyst, pdmp.research@odhsoha.oregon.gov